Free shipping on all orders over $ 500

Budigalimab

Cat. No. M24916
Budigalimab Structure
Synonym:

ABBV 181; PR 1648817

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function.

Chemical Information
CAS Number 2098225-93-3
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] F Peyraud, et al. Ann Oncol. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

[2] Stacie L Lambert, et al. J Immunother. Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

[3] Emiliano Calvo, et al. Cancer Treat Res Commun. Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer

[4] Antoine Italiano, et al. Cancer Immunol Immunother. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

[5] John Powderly, et al. Clin Transl Sci. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)

Related PD-1/PD-L1 Products
Rosnilimab

Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

Recombinant Anti-Mouse PD1 mAb

Recombinant Anti-Mouse PD1 mAb is a recombinant monoclonal antibody against the mouse PD1 protein, with the antibody isoform Mouse lgG1/lambda. the antibody efficiently binds to the mPD1 protein on the cell surface and significantly inhibits tumor growth in a mouse tumor model transplanted with MC38 cells. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell.

Erfonrilimab

Erfonrilimab is a humanized single-domain bispecific antibody-Fc fusion protein (VH-VH-h-CH2-CH3 dimer) targeting the immune checkpoints PD-L1 and CTLA-4.

Benmelstobart

Benmelstobart is an anti-PD-L1 humanized IgG1ҡ monoclonal antibody that can be used for tumor-related studies.

Human PD-L1 inhibitor II

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Budigalimab, ABBV 181; PR 1648817 supplier, PD-1/PD-L1, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.